眼表鳞状细胞瘤的药物治疗现状

来源 :中华眼外伤职业眼病杂志 | 被引量 : 0次 | 上传用户:jack607
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
眼表鳞状细胞瘤(OSSN)是眼表最常见的无色素肿瘤,手术切除是该类疾病最根本的治疗方式。“零接触”手术方式辅助冷冻疗法有助于避免肿瘤向周围组织扩散,但对于较大、累及视轴、复发性、多灶性或弥漫性病变,手术可能无法完全清除病灶,达不到理想的治疗效果,并且存在术后角膜缘干细胞缺乏、瘢痕形成和睑球粘连的风险。局部药物治疗由于药物接触整个眼表而具有明显优势,可以靶向治疗多灶性或弥漫性病变。应用较广泛的药物有5-氟尿嘧啶、丝裂霉素C和干扰素α2b三种,以及抗血管内皮生长因子药物、维甲酸、芦荟、西多福韦等。这些药物可以单独局部使用或者联合使用,也可以辅助术前减容、术后预防复发。了解OSSN的药物治疗现状有助于促进该领域研究。“,”Ocular surface squamous neoplasia(OSSN)is the most common unpigmented tumor on the ocular surface. Surgical resection is the most fundamental treatment. “ Non-contact” surgery assisted by cryotherapy is helpful to prevent the tumor from spreading to the surrounding tissue. However, for larger, axial, recurrent, multifocal or diffuse lesions, surgery may not be able to remove the lesions completely, leading to unsatisfactory therapeutic efficacy. Meanwhile, there is a risk of limbal stem cell deficiency, scar formation and symblepharon after surgery. Therefore, topical chemotherapy shows obvious advantages due to its action with the entire ocular surface, thus multifocal or diffuse lesions can be targeted for treatment. The most widely used drugs are 5-fluorouracil, mitomycin C, interferon α 2b, and others including anti-vascular endothelial growth factor agents, retinoic acid, aloe, cidofovir, etc., which can be applicated individually or in combination with each other. In addition, these medication also play an adjuvant role in preoperative treatment to reduce tumor volume as well as postoperative prevention of tumor recurrence. Better understanding of the pharmacological treatment of OSSN may promote the investigation in the future.
其他文献
【摘 要】建筑工程项目施工管理是建筑施工企业根据经营发展战略和企业内外条件,按照现代企业运行规律,通过生产诸要素的优化配置和动态管理,以实现工程项目的合同目标、工程经济效益和社会效益。本文通过分析建筑工程项目施工管理中存在的问题,阐述了项施工管理创新的必然性,提出了创新的原则和方案。  【关键词】工程项目;管理创新  建筑工程项目作为企业施工的主战场,不仅是展示企业形象的窗口、造就和培养企业管理人